Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Maze Therapeutics (MAZE) Shares Outstanding (2024 - 2026)

Maze Therapeutics' Shares Outstanding history spans 3 years, with the latest figure at $49.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 13.56% to $49.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $49.7 million, a 13.56% increase, with the full-year FY2025 number at $49.3 million, up 1916.28% from a year prior.
  • Shares Outstanding hit $49.7 million in Q1 2026 for Maze Therapeutics, up from $49.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for MAZE hit a ceiling of $49.7 million in Q1 2026 and a floor of $2.4 million in Q1 2024.
  • Historically, Shares Outstanding has averaged $27.2 million across 3 years, with a median of $43.8 million in 2025.
  • Biggest five-year swings in Shares Outstanding: soared 1916.28% in 2025 and later increased 13.56% in 2026.
  • Tracing MAZE's Shares Outstanding over 3 years: stood at $2.4 million in 2024, then soared by 1916.28% to $49.3 million in 2025, then rose by 0.81% to $49.7 million in 2026.
  • Business Quant data shows Shares Outstanding for MAZE at $49.7 million in Q1 2026, $49.3 million in Q4 2025, and $48.1 million in Q3 2025.